PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE
Clinical safety rating: safe
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
Pseudoephedrine is a sympathomimetic amine that acts as an indirect agonist at alpha- and beta-adrenergic receptors, causing vasoconstriction in the nasal mucosa and bronchodilation. Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms such as sneezing, rhinorrhea, and pruritus.
| Metabolism | Pseudoephedrine undergoes partial hepatic metabolism via N-demethylation to inactive metabolites; roughly 70-90% is excreted unchanged in urine. Triprolidine is extensively metabolized in the liver via hydroxylation and conjugation; its metabolism involves CYP450 enzymes, likely CYP3A4. |
| Excretion | Pseudoephedrine: ~70-90% renal as unchanged drug, minor hepatic metabolism (N-demethylation); Triprolidine: extensively hepatic metabolized, renal elimination of metabolites and unchanged drug (<5% unchanged), total excretion primarily renal and biliary. |
| Half-life | Pseudoephedrine: 5-8 hours (pH-dependent; alkaline urine increases half-life); Triprolidine: approximately 2-4 hours. Combined product: pseudoephedrine half-life is clinically relevant for dosing frequency. |
| Protein binding | Pseudoephedrine: ~50-70% bound to albumin and alpha-1 acid glycoprotein; Triprolidine: approximately 90% bound to plasma proteins. |
| Volume of Distribution | Pseudoephedrine: 2.5-3.5 L/kg; Triprolidine: 3-4 L/kg. Both indicate extensive tissue distribution, with pseudoephedrine distributing into breast milk and crossing blood-brain barrier. |
| Bioavailability | Pseudoephedrine: ~90% oral bioavailability; Triprolidine: ~95% oral bioavailability (first-pass metabolism minimal for triprolidine). |
| Onset of Action | Oral: Pseudoephedrine onset ~30-60 minutes; Triprolidine onset ~1-2 hours. |
| Duration of Action | Pseudoephedrine: 4-6 hours (immediate-release); Triprolidine: 4-6 hours. Product typically dosed every 4-6 hours. |
| Molecular Weight | Pseudoephedrine HCl: 201.7 Da; Triprolidine HCl: 314.9 Da |
| Action Class | Antihistamine and decongestant combination |
1 tablet (pseudoephedrine HCl 60 mg + triprolidine HCl 2.5 mg) orally every 4-6 hours, not to exceed 4 doses in 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR <30 mL/min: Avoid use. GFR 30-60 mL/min: Extend dosing interval to every 8-12 hours. GFR ≥60 mL/min: No adjustment. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Caution, consider extended interval (every 8-12 hours). Child-Pugh C: Avoid use due to reduced clearance and risk of toxicity. |
| Pediatric use | Children 6-12 years: 1/2 tablet (pseudoephedrine HCl 30 mg + triprolidine HCl 1.25 mg) every 4-6 hours, max 2 doses/24 hours. Children >12 years: Same as adult. Children <6 years: Not recommended. |
| Geriatric use | Initiate at lowest dose (1/2 tablet) every 6-8 hours due to increased sensitivity, reduced renal function, and higher risk of anticholinergic effects. |
| 1st trimester | Pseudoephedrine: Associated with increased risk of gastroschisis (odds ratio 1.8-2.0) in first trimester. Triprolidine: Limited data; animal studies show no teratogenicity. Avoid in first trimester due to potential risks. |
| 2nd trimester | Pseudoephedrine: Use only if clearly needed; may reduce uterine blood flow causing fetal hypoxia. Triprolidine: Generally considered safe; no major known risks. |
| 3rd trimester | Pseudoephedrine: Avoid near term due to risk of uterine artery vasoconstriction and fetal tachycardia. Triprolidine: Safe; but may cause neonatal respiratory depression if used near delivery. |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| FDA category | Animal |
| Placental transfer | Both pseudoephedrine and triprolidine cross the placenta. Pseudoephedrine: Readily crosses, with fetal:maternal ratio ~1.2. Triprolidine: Transfers but extent not well quantified. |
■ FDA Black Box Warning
None
| Common Effects | Sedation |
| Serious Effects | Hypertension, Tachycardia, Palpitations, Arrhythmias, Stroke, Myocardial infarction, Seizures, Psychosis, Urinary retention, Increased intraocular pressure |
Severe hypertensionCoronary artery diseaseConcurrent monoamine oxidase inhibitor therapy (current or within 14 days)Narrow-angle glaucomaUrinary retentionSevere hepatic or renal impairment
| Precautions | Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention due to sympathomimetic effects., May cause CNS stimulation, including insomnia, dizziness, or nervousness, especially in children., Avoid excessive dosage or prolonged use; may cause rebound congestion., Use with caution in patients with asthma, COPD, or respiratory depression; antihistamines may thicken bronchial secretions. |
Loading safety data…
| Breastfeeding | Pseudoephedrine: Excreted into breast milk in small amounts (0.5-0.7% of maternal dose); associated with infant irritability and reduced milk production. Triprolidine: Minimal excretion into breast milk; unlikely to cause adverse effects in infants. Combination product use during breastfeeding should be cautious, especially in premature or ill infants. |
| Lactation Rating | L4 (Possibly Hazardous) due to pseudoephedrine's effect on milk production |
| Teratogenic Risk | Limited human data; pseudoephedrine has been associated with gastroschisis in first trimester; triprolidine considered low risk. FDA Pregnancy Category C (pseudoephedrine) and B (triprolidine). First trimester: avoid due to potential vascular disruption; second/third trimester: use only if clearly needed, may reduce uterine blood flow and cause fetal tachycardia. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; fetal heart rate monitoring with prolonged use; assess amniotic fluid index if used near term. |
| Fertility Effects | No significant effects on fertility reported in humans; animal studies show no impairment. |
| Food/Dietary |
| Avoid alcohol and caffeinated beverages as they may increase risk of CNS stimulation or cardiovascular effects. High-tyramine foods (aged cheeses, cured meats) can theoretically cause hypertensive crisis with pseudoephedrine, but risk is low; however, caution advised. |
| Clinical Pearls | Pseudoephedrine is a sympathomimetic amine with decongestant properties; triprolidine is a first-generation antihistamine. This combination is used for allergic rhinitis and common cold symptoms. Caution in hypertension, cardiovascular disease, hyperthyroidism, and glaucoma. May cause CNS depression; avoid alcohol and sedatives. Not recommended in children under 4 years. Abuse potential due to pseudoephedrine; OTC sales are restricted in many jurisdictions. |
| Patient Advice | Take exactly as directed; do not exceed recommended dose. · Do not use if you have high blood pressure, heart disease, or take MAO inhibitors. · May cause drowsiness; avoid driving or operating machinery until you know how it affects you. · Do not take with other products containing pseudoephedrine or other stimulants. · If symptoms persist >7 days or worsen, consult a healthcare provider. · Store at room temperature away from moisture and heat. |